Aggarwal Sumit's most recent trade in Eloxx Pharmaceuticals Inc was a trade of 328,833 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 328,833 | 328,833 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 30,000 | 199,930 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharma | Sumit Aggarwal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| Eloxx Pharma | Aggarwal Sumit | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 165,000 | 169,930 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharma | Aggarwal Sumit | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 60,000 | 60,000 | - | - | Restricted Stock Units | |
| Eloxx Pharma | Sumit Aggarwal | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 68,700 | 68,700 | - | - | Stock Options (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 3,597,090 | 3,597,090 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 1,000,000 | 1,396,810 (3%) | 2% | 0 | Common Stock | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 260,946 | 3,336,144 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.15 per share. | 06 Feb 2022 | 260,946 | 1,672,756 (4%) | 0% | 0.2 | 39,142 | Common Stock |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 196,880 | 396,810 (0%) | 0% | 0.0 | 20 | Common Stock |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 Feb 2022 | 68,700 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 68,700 | 68,700 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 68,700 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 60,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 42,790 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 42,790 | 42,790 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 Feb 2022 | 42,790 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 42,790 | 42,790 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 35,580 | 35,580 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 Feb 2022 | 35,580 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 Feb 2022 | 24,810 | 0 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2022 | 24,810 | 24,810 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Eloxx Pharma | Sumit Aggarwal | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 15,000 | 1,411,810 (3%) | 0% | - | Common Stock |